<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01972477</url>
  </required_header>
  <id_info>
    <org_study_id>DLBS1449-0111</org_study_id>
    <nct_id>NCT01972477</nct_id>
  </id_info>
  <brief_title>DLBS1449 in Diabetic Patients With Low HDL</brief_title>
  <official_title>The Effect of DLBS1449 in Diabetic Patients With Low HDL-Cholesterol - Double Blind Comparative Study With Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dexa Medica Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dexa Medica Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a parallel, 3-arm, randomized, prospective, placebo-controlled, and double-blind&#xD;
      clinical study for eight weeks of therapy to investigate the clinical efficacy of DLBS1449 in&#xD;
      elevating high density lipoprotein (HDL) cholesterol in diabetic patients. The hypothesis of&#xD;
      interest for the study is: the administration of DLBS1449 will elevate HDL-cholesterol level&#xD;
      from baseline to the end of study significantly higher than the elevation resulted by&#xD;
      placebo. In addition, the administration of DLBS1449 at the dose of 150 mg daily will provide&#xD;
      a significantly better response than that of the lower dose (DLBS1449 75 mg daily).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be three groups of treatment by dosage regimen in this study. Eligible subjects&#xD;
      will be randomized to receive any of the following regimens: 1) DLBS1449 at a dose of 1 x 75&#xD;
      mg daily, or 2) DLBS1449 at a dose of 1 x 150 mg (two capsules of DLBS1449 75 mg) daily; or&#xD;
      3) placebo, once daily. Study medication should be administered once daily, in the evening&#xD;
      with meal, for eight weeks. Clinical and laboratory examinations to evaluate investigational&#xD;
      drug's efficacy and safety will be performed at baseline and at interval of four weeks over&#xD;
      8-week course of therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in HDL-cholesterol level</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in HDL-cholesterol level</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in LDL-cholesterol level</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in sd LDL-cholesterol level</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in triglycerides level</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in total cholesterol level</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Apo-A1</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Apo-B</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Response rate is defined as percentage of subjects with HDL-cholesterol &gt;= 40 mg/dL after 8 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in A1c level</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>4 and 8 weeks</time_frame>
    <description>Vital signs measurements include: blood pressure, heart rate, and respiratory rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Routine hematology</measure>
    <time_frame>4 and 8 weeks</time_frame>
    <description>Routine hematology measurements include: hemoglobin, hematocrit, RBC, WBC, differentiation of WBC, and platelet count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>4 and 8 weeks</time_frame>
    <description>Liver function measurements include: serum ALT, serum AST, gamma-GT, and alkaline phosphatase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>4 and 8 weeks</time_frame>
    <description>Renal function measurement includes: serum creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiography (ECG)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The interpretation of ECG result will be recorded. Any worsened changes from baseline condition will be counted as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>1-8 weeks</time_frame>
    <description>Adverse event will be observed and recorded during the study period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetic Patients</condition>
  <condition>Low HDL-cholesterol (&lt; 35 mg/dL)</condition>
  <condition>Lifestyle Intervention for at Least 1 Month</condition>
  <arm_group>
    <arm_group_label>DLBS1449, 1x75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DLBS1449 softcapsule 1x75 mg daily, taken every day along the study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DLBS1449, 1x150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DLBS1449 softcapsule 1x150 mg (2 softcapsules 75 mg) daily, taken every day along the study period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily, taken every day along the study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DLBS1449</intervention_name>
    <description>Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.</description>
    <arm_group_label>DLBS1449, 1x150 mg</arm_group_label>
    <arm_group_label>DLBS1449, 1x75 mg</arm_group_label>
    <other_name>Forhidrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given every day for 8 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 21 - 70 years.&#xD;
&#xD;
          -  Have been diagnosed diabetes mellitus and being treated with lifestyle intervention&#xD;
             for at least 1 month prior to screening, with or without antidiabetic agents.&#xD;
&#xD;
          -  HDL-cholesterol level of &lt; 35 mg/dL.&#xD;
&#xD;
          -  Triglycerides level of &lt; 200 mg/dL.&#xD;
&#xD;
          -  Adequate liver and renal function.&#xD;
&#xD;
          -  Statin and/or fenofibrate therapy should have been being regularly taken for &gt;=3&#xD;
             months at stable dose (ONLY for subjects currently under statin and/or fenofibrate&#xD;
             therapy).&#xD;
&#xD;
          -  Able to take oral medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding women or willing to be pregnant.&#xD;
&#xD;
          -  Symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.&#xD;
&#xD;
          -  Uncontrolled hypertension (SBP &gt; 160 mmHg and/or DBP &gt; 100 mmHg).&#xD;
&#xD;
          -  Any other disease state, including chronic/acute systemic infections, uncontrolled&#xD;
             illnesses or other chronic diseases, which judged by the investigator, could interfere&#xD;
             with trial participation or trial evaluation.&#xD;
&#xD;
          -  Concurrent treatment with systemic corticosteroids or herbal (alternative) medicines.&#xD;
&#xD;
          -  Known allergic or hypersensitive to drugs contain similar active substance with the&#xD;
             study medication.&#xD;
&#xD;
          -  Participation in any other clinical studies within 30 days prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Askandar Tjokroprawiro, Prof, SpPD, K-EMD, FINASIM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Surabaya Diabetes and Nutrition Center, Dr. Soetomo Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surabaya Diabetes and Nutrition Center, Dr. Soetomo Hospital; Pusat Diagnostik Terpadu Building 7th Floor</name>
      <address>
        <city>Surabaya</city>
        <state>East Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>October 24, 2013</study_first_submitted>
  <study_first_submitted_qc>October 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2013</study_first_posted>
  <last_update_submitted>August 3, 2016</last_update_submitted>
  <last_update_submitted_qc>August 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBS1449</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>HDL-cholesterol</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

